For decades, surgical resection was considered the gold standard for the treatment of liver cancer. Percutaneous ablation was often viewed as an option, reserved for patients who were not candidates for surgery.
Over the past decade, that paradigm has shifted significantly. Driven by advances in clinical practice, evidence, and technological innovation, percutaneous ablation has evolved into a recognized first-line treatment option for selected patients with primary and secondary liver tumors. This transformation is increasingly reflected in international clinical guidelines and everyday clinical practice.
Clinical guidelines play a critical role in modern cancer care. They translate scientific evidence and expert consensus into practical recommendations that help physicians and multidisciplinary tumor boards define the most appropriate treatment strategy for each patient.
Among the most influential oncology guidelines are those published by NCCN, ASCO and ESMO. For liver cancer specifically, additional guidance is provided by organizations such as EASL, AASLD and JSH, as well as the internationally recognized Barcelona Clinic Liver Cancer (BCLC) framework. Together, these guidelines shape treatment decisions for patients around the world and are regularly updated as new clinical evidence emerges.
The role of percutaneous ablation has changed substantially over the past two decades. This evolution can broadly be divided into four distinct phases.
A Palliative Alternative (2005-2011): During the early years, clinical evidence was limited and outcomes varied considerably between centers. As a result, ablation was generally recommended when surgical resection was not feasible or appropriate. Its use remained restricted to a relatively small and carefully selected group of patients.
Emerging Curative Potential (2012–2017): As clinical evidence accumulated, studies demonstrated that ablation could achieve curative outcomes in carefully selected patients with early-stage disease. Guidelines increasingly acknowledged this potential, although surgery remained the preferred treatment in many situations. Clinical adoption gradually expanded.
A Curative-Intent Treatment Modality (2018–2022): Growing evidence demonstrated comparable local tumor control and survival outcomes between surgery and ablation for selected indications. Consequently, major guidelines increasingly incorporated ablation into curative treatment pathways, contributing to broader clinical acceptance.
Establishment as a First-Line Option (2023–2026): Recent high-quality studies, including the MAVERRIC and COLLISION trials, have provided some of the strongest evidence to date. These studies demonstrated comparable overall survival between ablation and surgical resection for selected patients with small colorectal liver metastases (CRLM ≤3 cm), while showing important advantages such as lower complication rates, shorter hospital stays, and reduced healthcare costs. Consequently, major guidelines increasingly recognize ablation as a curative treatment option on par with surgery an, in selected patients, as a preferred first-line local treatment.
The evolution of clinical evidence and guidelines has been accompanied by significant technological progress. Ablation technologies have become more sophisticated and predictable, while imaging, navigation, and decision support solutions have improved physicians' ability to plan procedures, place probes accurately, and assess treatment success. At the same time, the field has increasingly recognized that successful ablation involves more than simply placing an applicator and delivering energy. Achieving adequate ablation margins and objectively assessing treatment outcomes have become central elements of modern ablation practice. Together, these developments are helping move percutaneous ablation toward more standardized, reproducible and measurable treatment workflows.
The progress over the past 20 years has been substantial. Yet further work is required before all eligible patients can benefit from percutaneous ablation.
Increasing Awareness: Treatment decisions within multidisciplinary tumor boards may still be influenced by historical perceptions of ablation. Ensuring that decisions reflect current evidence, contemporary technology and the latest guideline recommendations will be important for appropriate patient selection.
Expanding Clinical Evidence: Further studies are needed to determine how consistently the outcomes demonstrated in experienced centers and clinical trials can be reproduced across broader healthcare systems, institutions and patient populations. Continued evidence generation will also help define which patients and tumor characteristics benefit most from an ablative approach.
Standardizing Best Practices: Clinical practice remains heterogeneous, and outcomes can vary between institutions. Recent international Delphi consensus initiatives21,22 led by experts from MD Anderson Cancer Center in Houston and the Medical University of Innsbruck represent important steps toward defining best practices for safe and effective ablation. Their implementation in routine clinical practice could be critical to improving consistency and outcomes across centers.
Embracing AI and New Technologies: Technology often advances faster than clinical evidence and guidelines. It is therefore important to remain open to innovations that can further advance ablation — whether through new ablation modalities, navigation and decision support technologies, or quantitative margin assessment.
Establishing the Economics: Clinical evidence alone is not always sufficient to drive widespread adoption. New technologies must also demonstrate a compelling economic case, whether through dedicated reimbursement or by showing that their clinical and operational benefits justify the costs within existing funding structures. As healthcare economist David Cutler has emphasized, medical innovations are ultimately adopted when healthcare systems recognize the value they create.23
Percutaneous ablation has undergone a remarkable evolution over the past two decades. Significant clinical, scientific, and technological efforts have transformed it from an alternative into an increasingly recognized first-line treatment option for selected patients.
Ensuring that this evolution continues will require a shared commitment. Clinicians must advocate for the best treatment options for their patients, implement standardized procedures and contribute to further evidence generation. Industry must continue to develop technologies that make treatments safer, more effective, and more reproducible. And healthcare systems must recognize both the clinical and economic value that minimally invasive treatments can provide.
The opportunity is clear: to enable more patients to benefit from minimally invasive treatments that deliver excellent oncological outcomes while reducing treatment burden and preserving quality of life.
At CASCINATION, we embrace this challenge. We are proud to contribute to the continued evolution of percutaneous ablation.